{"id":43507,"date":"2025-10-15T22:29:39","date_gmt":"2025-10-15T14:29:39","guid":{"rendered":"https:\/\/flcube.com\/?p=43507"},"modified":"2025-10-15T22:29:40","modified_gmt":"2025-10-15T14:29:40","slug":"china-resources-double-crane-partners-with-rigerna-on-sirna-drug-rg008-for-chronic-metabolic-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43507","title":{"rendered":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases"},"content":{"rendered":"\n

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062<\/a>) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.<\/p>\n\n\n\n

Rigerna’s Technology Platform<\/strong>
Rigerna, a pioneer in the siRNA field, has established the proprietary SRNA technology platform. This platform holds global intellectual property rights and encompasses core technologies such as delivery vectors, chemical modification, and sequence selection.<\/p>\n\n\n\n

Clinical Progress<\/strong>
Rigerna’s lead candidate, RG002, for the treatment of kidney diseases like IgA Nephropathy (IgAN), has initiated Phase I clinical trials. This progress places Rigerna at the forefront globally and provides initial validation of the clinical potential of its technology platform.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into…<\/p>\n","protected":false},"author":1,"featured_media":43511,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[2238,4388,64,2236],"class_list":["post-43507","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-china-resources-double-crane-pharmaceutical","tag-rigerna-therapeutics","tag-rnai-aso","tag-sha-600062"],"yoast_head":"\nChina Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43507\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases\" \/>\n<meta property=\"og:description\" content=\"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43507\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T14:29:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T14:29:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases\",\"datePublished\":\"2025-10-15T14:29:39+00:00\",\"dateModified\":\"2025-10-15T14:29:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507\"},\"wordCount\":131,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505-1.webp\",\"keywords\":[\"China Resources Double-Crane Pharmaceutical\",\"Rigerna Therapeutics\",\"RNAi \\\/ ASO\",\"SHA: 600062\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43507#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43507\",\"name\":\"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505-1.webp\",\"datePublished\":\"2025-10-15T14:29:39+00:00\",\"dateModified\":\"2025-10-15T14:29:40+00:00\",\"description\":\"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43507\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1505-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43507#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases - Insight, China's Pharmaceutical Industry","description":"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43507","og_locale":"en_US","og_type":"article","og_title":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases","og_description":"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.","og_url":"https:\/\/flcube.com\/?p=43507","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T14:29:39+00:00","article_modified_time":"2025-10-15T14:29:40+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43507#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43507"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases","datePublished":"2025-10-15T14:29:39+00:00","dateModified":"2025-10-15T14:29:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43507"},"wordCount":131,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43507#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","keywords":["China Resources Double-Crane Pharmaceutical","Rigerna Therapeutics","RNAi \/ ASO","SHA: 600062"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43507#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43507","url":"https:\/\/flcube.com\/?p=43507","name":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43507#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43507#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","datePublished":"2025-10-15T14:29:39+00:00","dateModified":"2025-10-15T14:29:40+00:00","description":"China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into a collaboration agreement to jointly develop RG008, an innovative small interfering RNA (siRNA) drug targeting chronic metabolic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43507#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43507"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43507#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","width":1080,"height":608,"caption":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43507#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1505-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43507"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43507\/revisions"}],"predecessor-version":[{"id":43512,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43507\/revisions\/43512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43511"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}